ข่าวประชาสัมพันธ์ Acute Coronary Syndrome

New ESC Guidelines Recommend Efient(R) (Prasugrel) as First-line Antiplatelet Therapy for Patients with Non-ST Segment Myocardial Infarction and Unstable Angina Acute Coronary Syndromes

In new guidelines from the European Society of Cardiology (ESC), prasugrel a once daily oral antiplatelet medicine received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI a type of heart attack and unstable angina or UA).(1) The highest available recommendation, Class I recognizes that prasugrel is

01 กันยายน 2554 08:31 น.

New ESC Guidelines Recommend BRILIQUE (ticagrelor) in all Moderate-To-High Risk Patients With Non-ST Elevation Acute Coronary Syndromes

- This release is not intended for US media Ticagrelor Recommended for Medically & Invasively Managed NSTE-ACS Patients Regardless of Prior Treatment with... ส.ค. 54

Phase II Study Showed Switching ACS-PCI Patients on Maintenance Clopidogrel/Aspirin to Prasugrel/Aspirin Reduced Maximal Platelet Aggregation After One Week

In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient(R)... ก.ย. 53

Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes

- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The... ส.ค. 52

ภาควิชาอายุรศาสตร์และสาขาวิชาหทัยวิทยา คณะแพทยศาสตร์ศิริราชพยาบาล Cardiac Biomarkers in Acute Coronary Syndrome: Emphasizing High Sensitive Troponin

ภาควิชาอายุรศาสตร์และสาขาวิชาหทัยวิทยา คณะแพทยศาสตร์ศิริราชพยาบาล จัดบรรยายวิชาการเรื่อง Cardiac Biomarkers in Acute Coronary Syndrome: Emphasizing high... ส.ค. 52

U.S. Regulators Approve Prasugrel for Reduction of Cardiovascular Events In Patients with Acute Coronary Syndromes Managed with Artery-Opening Procedure

Daiichi Sankyo Company, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient... ก.ค. 52

European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

Heart patients with acute coronary syndrome (ACS) undergoing an artery-opening procedure will soon have a new treatment option to help prevent heart attacks. Daiichi Sankyo Company, Limited ... ก.พ. 52

New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)

- A new Step Forward may Help Increase Appropriate Early use of Plavix(R) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi-aventis (EURONEXT: SAN and... มี.ค. 51

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering from Acute Coronary Syndrome

sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST... ก.ย. 50